Dabigatran
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Cardiac & Hypertension treatment.
🧴 Clinical Application
Swallow capsules whole with a full glass of water, with or without food. Never open, crush, break, or chew capsules, as opening increases oral bioavailability by 75%, drastically increasing bleeding risk. Keep in the original blister pack or desiccant-containing bottle; sensitive to moisture.
⚠️ Side Effects
Common: Dyspepsia, epigastric pain, nausea, minor bleeding, gastrointestinal discomfort. Rare/Severe: Boxed warnings: Thrombotic events after premature discontinuation; spinal/epidural hematomas; major gastrointestinal or intracranial hemorrhage.
🛡️ Safety Warnings
Black box warnings for stroke on premature stopping and spinal hematoma. Capsules must be swallowed whole; opening capsules causes dangerous overdose. Predominantly eliminated by kidneys (80%); contraindicated in severe renal impairment (CrCl < 30 mL/min). Contraindicated with mechanical prosthetic heart valves.
Jan Aushadhi Products containing Dabigatran
Found 3 generic formulation(s) containing this active ingredient.
Dabigatran Etexilate Mesilate Capsules 110 mg
Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.
Dabigatran Etexilate Mesilate Capsules 150 mg
Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.
Dabigatran Etexilate Mesilate Capsules 75 mg
Dabigatran Etexilate is an oral prodrug of dabigatran, a potent, competitive, reversible direct thrombin (Factor IIa) inhibitor on the WHO Model List of Essential Medicines. It binds to the active site of both free and clot-bound thrombin, preventing thrombin-mediated conversion of fibrinogen into fibrin and blocking thrombin-induced platelet aggregation. Specific reversal agent (idarucizumab) is available. Indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prophylaxis of DVT and pulmonary embolism.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Dabigatran.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Dabigatran Etexilate Mesilate Capsules 110 mg | 10's | ₹128.91 | PRADAXA | ₹323.74 | 60% Save |
| Dabigatran Etexilate Mesilate Capsules 150 mg | 10's | ₹165.00 | PRADAXA | ₹354.35 | 53% Save |
| Dabigatran Etexilate Mesilate Capsules 75 mg | 10's | ₹122.81 | DABIGAT, PRADAXA | ₹430.77 | 71% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Dabigatran generics.